Lori Mayer

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

Lori Mayer, Ludwig Kappos, Michael K. Racke et al. · Multiple Sclerosis and Related Disorders · 2019 · 97 citations

Pharmacy, Neurology, Pharmacotherapy +10

Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships

Ann Bass, Bart Van Wijmeersch, Lori Mayer et al. · International Journal of MS Care · 2019 · 61 citations · Full text

Nursing, Neurology, Psychology +17

Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) Program

Christina Caon, Marie Namey, Cathy Meyer et al. · International Journal of MS Care · 2015 · 47 citations · Full text

Life Sciences, Clinical Sciences, Pharmacology +17

A single‐arm, open‐label study of alemtuzumab in treatment‐refractory patients with multiple sclerosis

Edward Fox, H. R. Sullivan, Suzanne Gazda et al. · European Journal of Neurology · 2011 · 45 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14

Effects of Functional Electrical Stimulation on Gait Function and Quality of Life for People with Multiple Sclerosis Taking Dalfampridine

Lori Mayer, Tina Warring, Stephanie Agrella et al. · International Journal of MS Care · 2014 · 27 citations

Medicine, Neurology, Rehabilitation Medicine +17